suggests that BTN3A, itself part of the molecular complex required for phosphoantigen-mediated activation of Vγ9Vδ2+ T cells, can also inhibit tumor-reactive CD8+ αβ T cells when bound to N-mannosylated residues of CD45 by preventing its segregation from the immunological synapse (52). The gene discussed is CD8A; the disease is neoplasm.